Discover selected sets of Building Blocks in the Chemspace 'Molecule Builder' series for the synthesis of analogs of recently approved drugs!

 

For the synthesis of related compounds, a key intermediate step might involve the coupling of substituted 1,3,5-triazines with trifluoroalkylamines. Discover two comprehensive sets of Building Blocks – substituted 1,3,5-triazines (133 compounds) and fluoroalkylamines (318 compounds), offering an ideal starting point for your research.

 

Vorasidenib, recently approved by the FDA under the brand name VORANIGO®, is an oral, first-in-class dual inhibitor targeting mutant Isocitrate dehydrogenase 1 and Isocitrate dehydrogenase 2 enzymes. These mutations are frequently found in gliomas and other cancers, making Vorasidenib a promising treatment option for patients with these challenging conditions. By inhibiting the mutant IDH enzymes, Vorasidenib helps reduce the production of the oncometabolite 2-hydroxyglutarate, thereby slowing tumor growth and progression.

 

Explore our comprehensive selection of in-stock and make-on-demand molecules at chem-space.com. Interested or have any questions? Contact us at sales@chem-space.com.

 

Chemspace | “Molecule Builder”- meet a new post in the series about Vorasidenib! We are delighted to continue our series in Molecule Builder! Vorasidenib, also known by the brand name VORANIGO®, is an oral, first-in-class dual inhibitor targeting mutant IDH1 and IDH2.